Cocrystal ubiquinol: a small pharmacokinetic comparison
Cocrystal formulation evidence · human pharmacokinetics
Mei et al. · 2026 · Clin Pharmacol Drug Dev
Study details
- Evidence Type
- Double-blind two-period crossover pharmacokinetic pilot
- Studied Material / Formulation
- A cocrystal ubiquinol softgel compared with a standard ubiquinone softgel.
- Population
- 12 healthy adults
- Dose
- 240 mg in each arm as two 120 mg softgels, under fasting conditions.
- Duration
- One dose in each period, with 48-hour sampling and a 14-day washout.
- Main Findings
- The tested cocrystal ubiquinol softgel produced higher systemic exposure than its ubiquinone comparator.
- Limitations
- Not conventional ubiquinol as comparator; not DR.MORGAN 100 mg hard capsules. Small single-dose PK study, not evidence of better clinical outcomes.
- Product Relevance
- Indirect relevance; different dose/formulation
- DR.MORGAN finished product studied
- NO
This study was not conducted on the finished DR.MORGAN product.
Funding and disclosures
Cocrystal Health Industry funded the work and supplied both study products. One author lists an affiliation with the company.